CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Efficacy and safety of Empagliflozin in younger, overweight/obese patients with Type 2 diabetes with HbA1c ≥8%
DOI 10.1055/s-0035-1549618
Bibliografische Angaben
Nachweis in CareLit
Autor:innenL Merker, SS Lund, S Hantel, A Salsali, G Kim, UC Broedl, HJ Woerle, T Hach
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aim: To assess the efficacy and safety of empagliflozin in younger, overweight/obese patients with type 2 diabetes (T2DM) with HbA1c ≥8%. Methods: Using pooled data from 4 randomized Phase III trials in patients with T2DM, we conducted a post-hoc analysis of patients aged < 65 years with BMI ≥25 to < 35 kg/m2 and HbA1c ≥8% at baseline, who received empagliflozin 10 mg (n = 193), empagliflozin 25 mg (n = 179) or PBO…
Zitieren
Zitierempfehlung
L Merker, SS Lund, S Hantel, A Salsali, G Kim, UC Broedl, HJ Woerle, T Hach (2015) Efficacy and safety of Empagliflozin in younger, overweight/obese patients with Type 2 diabetes with HbA1c ≥8%. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0035-1549618
Mit CareLit weiterarbeiten